Table 1Submitted for Review

Item Description
Drug product Abemaciclib (Verzenio), 50 mg, 100 mg, 150 mg, 200 mg oral tablet
Submitted price Abemaciclib, 50 mg: $98.4714 per tablet

Abemaciclib, 100 mg: $99.9704 per tablet

Abemaciclib, 150 mg: $98.4714 per tablet

Abemaciclib, 200 mg: $99.9704 per tablet

Indication Indicated in combination with ET for the adjuvant treatment of adult patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of disease recurrence based on clinicopathologic features and a Ki-67 score ≥ 20%
Health Canada approval status NOC
Health Canada review pathway Standard review
NOC date January 12, 2022
Reimbursement request As per indication
Sponsor Eli Lilly Canada Inc.
Submission history Previously reviewed: Yes

Indication: Advanced or metastatic breast cancer

  • Recommendation date: July 5, 2019
  • Recommendation: Reimburse with clinical criteria and/or conditions

ET = endocrine therapy; HER2 = human epidermal growth factor receptor 2; HR = hormone receptor; NOC = Notice of Compliance.

From: Pharmacoeconomic Review

Cover of Abemaciclib (Verzenio)
Abemaciclib (Verzenio): CADTH Reimbursement Review: Therapeutic area: Adjuvant treatment of hormone receptor–positive, human epidermal growth factor receptor 2–negative early breast cancer [Internet].
Copyright © 2022 Canadian Agency for Drugs and Technologies in Health.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.